This article examines trends in antipsychotic medication use in a treated population of publicly funded patients with schizophrenia between 1991 and 1996. Findings from administrative claims data show that antipsychotic prescription rates increased from 79 percent to 83 percent between 1991 and 1996. Atypical antipsychotics were used by 39 percent of the population and comprised 41 percent of all antipsychotic agents prescribed compared to 59 percent for typical agents. Duration on a typical agent was 8 months versus 7.4 months for newer atypicals, with duration 11 months for those on clozaplne. The highest switching behavior is found in users of atypicals (58% versus 25% for those on typicals) as is the percent of those who received an antidepressant concurrently with an antipsychotic, which was 44 percent for newer atypical users versus 31 percent for typical users. The lowest antidepressant use was among clozaplne users (28%). Atypical users were more likely to be younger Caucasian men with higher use of inpatient and ambulatory mental health services compared to those on typical medications. The newer antipsychotic medications appear to be displacing traditional medications; however, contrary to what the literature suggests, duration is shorter and switching behavior and concurrent use of antidepressants is higher than in typical users.
In recent years, the arrival of atypical antipsychotics for treating patients with schizophrenia has received considerable attention from psychiatrists, consumers, health policy experts, health insurance organizations, and mental health services researchers. Given the severe side effects associated with many of the older antipsychotics, the introduction of atypicals, which appear to produce far fewer extrapyramidal side effects and show properties associated with reduced negative symptoms, has been greeted enthusiastically by psychiatrists and consumers (Sheitman et al. 1997; Zito 1998; Siris 2000) . Unfortunately, few studies have tracked the degree of penetration of atypical psychotropic medications among schizophrenia patients in general and more specifically among those receiving health care through Medicaid, the publicly funded health care insurance program for the disabled and low-income population. Part of the difficulty in ascertaining this information is that most national probability and private-payer sample surveys of medication use do not yield sufficient sample sizes to support statistical analysis because of the low prevalence of schizophrenia in the general population.
One of the few studies examining antipsychotic medication use was the Schizophrenia Patient Outcome Research Team study (PORT) . Investigators found that in a study of 440 outpatients, 92 percent received antipsychotic medications (Lehman et al. 1998a (Lehman et al. , 1998 . A comparison between Department of Veterans Affairs (VA) and non-VA outpatients (n = 457) showed that 81 percent of VA patients and 92 percent of non-VA patients received antipsychotic medications (Rosenheck et al. 2000) . Little information is available on atypical agents though, as this study was done prior to their proliferation. In a study examining Medicaid patients in the California MediCal program (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) , McCombs et al. (1999) found that 76 percent of patients with a diagnosis of schizophrenia received psychotropic medications. Only 3 percent received an atypical because of strict formulary restrictions in the MediCal program.
A survey that provides some information on prescription trends is the National Ambulatory Medical Care Sur-vey, which found that between 1980 and 1989 the number of visits during which an antipsychotic was prescribed remained stable, although shifts occurred in the type of antipsychotic agent prescribed (Olfson and Klerman 1993; Olfson et al. 1998) . Haloperidol was the most frequently prescribed antipsychotic agent in the 1980s and early 1990s. Clozapine was just beginning to be used for treatment-resistant patients during this period (Johnson and McFarland 1993; Baldessarini et al. 1995) . In the mid1990s, newer atypical antipsychotics such as risperidone (1993) and olanzapine (1996) were introduced for the treatment of schizophrenia. A study by Wang et al. (2000) as well as pharmaceutical reports (Lehman 1999) suggested that atypicals made up more than 50 percent of the antipsychotic medication market. An empirically based study using claims data showed that 58.7 percent of treated patients with schizophrenia in the VA medical system (n => 35,000) were prescribed an atypical agent, including clozapine, over a 4-month period in 1999 (Leslie and Rosenheck 2001) .
According to treatment recommendations provided by the PORT study (Lehman et al. 1998a) , antipsychotic medications should be continued for at least 1 year subsequent to symptom stabilization. The American Psychiatric Association (APA) guidelines for those who have experienced multiple episodes advise continuation for 5 years or possibly indefinitely (APA 1997) . In contrast to the recommendations, empirical evidence of duration on conventional antipsychotics in community populations showed average duration to be 4.7 months in the MediCal population (McCombs et al. 1999 ) and 5.6 months in a health maintenance organization population (Wang et al. 2000) . A recent meta-analysis (Cramer and Rosenheck 1998) found that only 58 percent of schizophrenia patients adhered to their medication regimen. This analysis was consistent with Lehman et al's (1998fc) findings from the PORT study, which indicated that conformance with recommended treatment on antipsychotics was below 50 percent. Furthermore, 47 percent of MediCal patients switched from one conventional antipsychotic to another (McCombs et al. 1999) , suggesting that medications were not working effectively.
In addition to duration and switching problems, a further complicating factor in medication therapy for schizophrenia is depression. Approximately 25 percent of patients are estimated to have comorbid depression leading to high cotreatment with antidepressants (Siris 2000) . In the PORT study, 45 percent of comorbid persons were prescribed an antidepressant. The antipsychotic agents in the PORT study were primarily conventional antipsychotics or conventional neuroleptics. The newer antipsychotic medications are purported to have mood-stabilizing effects that should provide better symptom relief for depression and perhaps decrease antidepressant prescription levels (Siris 2000) .
Based on a recent review of clinical trial evidence, participants in a National Institute of Mental Health workgroup concluded that atypicals were more effective than traditional antipsychotics and should be considered the first line of treatment for patients with schizophrenia (Dawkins et al. 1999 ). Other than the two studies on MediCal patients in California, where atypicals were not in the formulary (McCombs et al. 1999 (McCombs et al. , 2000 , the PORT study, which was prior to the penetration of atypical medication in the marketplace, and the veteran population studies, which had over 50 percent atypical medication rates (Rosenheck et al. 2000; Leslie and Rosenheck 2001) , little is known about rates and patterns of use of atypical antipsychotics for patients in community settings. As more States mandate the enrollment of Medicaid recipients with mental disabilities in managed care programs, concerns arise that the newer atypical medications will be restricted by managed care formularies. Coffey et al. (2000) found that the share of expenditures for drugs increased from 8 percent to 13 percent of mental health spending between 1987 and 1997 and was expected to rise even more. It is therefore essential that psychotropic medication patterns of schizophrenia patients in public sector programs be monitored to ensure equity and appropriateness of treatment (Johnson and McFarland 1993) .
This article examines the trends and patterns of psychotropic medication use from 1991 to 1996 for a large urban treated population of publicly funded patients with schizophrenia. Claims data from a State fee-for-service Medicaid program that does not restrict the use of atypical antipsychotics were used to monitor large numbers of patients over time. Medicaid data provided an excellent source of information on individuals with schizophrenia because the Medicaid program funds a large portion of mental health treatment in routine community settings (Zito 1998 
Methodology
Subject Selection. Study subjects were adults (18-64 years old) enrolled in a Medicaid fee-for-service program between 1991 and 1996 who had at least one "ambulatory" visit with a primary clinical diagnosis of schizophrenia and schizoaffective disorders (ICD-9 295). Study subjects had visits to either the specialty mental health or general health care sectors (i.e., physician visits). The Medicaid mental health benefit for psychotropic prescriptions provided comprehensive coverage so that the newer atypical medications were part of the formulary. However, because hospital pharmacy data were not included in the paid claims files, 5 percent of the study population with an inpatient episode only were excluded because we could not identify the indexed prescription date.
Data. Medicaid enrollment files and paid claims records on services and pharmacy for Philadelphia residents enrolled in the Medicaid program were used to develop annual rates of psychotropic use between January 1991 and December 1996. Enrollment data files were used to determine the time period that subjects were eligible for Medicaid. Paid claims records were used to determine psychiatric service and medication use. Service records indicated diagnosis, date of service, provider, and type of service as well as important patient sociodemographic characteristics such as age, race, and gender. Pharmacy records contained patient information as well as drug type, date prescription was filled, dosage, national drug code (NDC), and so on. Person-level identifiers were used to match individuals who had at least one mental health ambulatory visit annually with a clinical diagnosis of ICD-295, with antipsychotic medication records. Antipsychotic agents were assigned a drug product name based on the 11-digit NDC drug code, and generic names were assigned to each agent based on information obtained from the Physician Desk Reference and State Medicaid pharmacy files.
Study Design. For the trend analysis, a cross-sectional annual treated prevalence sample was chosen for each of 6 years (1991) (1992) (1993) (1994) (1995) (1996) . Subjects had to be eligible for Medicaid at some point during the year that their visit occurred and have at least one ambulatory visit with a diagnosis of schizophrenia during the year they were identified. Annual rates of antipsychotic prescription use were constructed for overall antipsychotic prescriptions and for different types of antipsychotic medications (conventional vs. atypicals such as clozapine, risperidone, and olanzapine), as were rates of depot medication use. To distinguish between those prescribed or not prescribed medication, we compared characteristics of subjects in 1995 and employed chi-square tests of significance for categorical variables and t tests for continuous variables. For the purposes of this study, persons prescribed medication had to have filled the prescription in order to generate a record or claim. Those in the no-prescription group may have received a prescription but never had it filled.
To answer questions related to prescription patterns such as duration, switching, and concurrent prescription of antidepressants, we selected subjects who were prescribed antipsychotic medications in 1995. All subjects' first 1995 antipsychotic prescription claim was identified as the indexed prescription, and their use patterns were constructed for the year following their index date. Only subjects who were "continuously" eligible for Medicaid for 1 year following their indexed prescription were selected. A subject could have received antipsychotic medications in a previous year, as there was no way to ascertain first episode of medication treatment. Three groups were constructed based on the type of indexed prescription: conventional (i.e., haloperidol, fluphenazine, loxapine, and so on), and clozapine and newer atypicals (i.e., primarily risperidone). The groups were compared with respect to sociodemographic and service characteristics, as well as duration, switching patterns, and concurrent medication use.
Monthly data were constructed for each individual with indicators for type of medication agent used. Duration was defined as the number of months in a year on a medication from the indexed prescription date; concurrent use referred to polypharmacy or additional medications prescribed during that period. An interruption in prescriptions was defined as 2 months with no medication claim; switching, according to our definition, was reflected in no use of the indexed agent for at least 2 months after a new one was started and the other one stopped. This approach allowed us to capture a new medication that began while the indexed one was phased out Analysis of variance tests of significance were used to compare continuous variables such as age and duration across groups; chi-square tests were employed to compare rates of use by type of atypical agent, the percentage of patients who switched medications, and the percentage of patients who received concurrent medications.
Results
Trend Analysis. Figure 1 shows that the prescription rate of antipsychotic medications in schizophrenia patients remained fairly constant between 1991 and 1996, ranging from 79 percent to 83 percent of the adult treated population. Approximately 5,000 individuals received outpatient treatment for schizophrenia in the public mental health system each year. As hypothesized, we saw a continual increase in the use of atypicals corresponding to their arrival in the marketplace. Individuals prescribed clozapine increased from 3 percent to 10 percent, while those 
(n = 4681)
Year on other atypicals climbed from 14 percent to 31 percent over a 2-year period. By 1996, 39 percent of individuals received some type of atypical agent Six percent of atypicals appearing in the files in 1996 were olanzapine; the predominant newer atypical antipsychotic agent was risperidone (28%) at that time.
There appeared to be some substitution of atypicals for conventional medications, as the rate of conventional agents decreased from 79 percent in 1991 to 64 percent in 1996. The most prominent conventional agent, haloperidol, decreased slightly from a high of 31 percent in 1991 to 28 percent in 1996. Depot injections, which included haloperidol and fluphenazine, were used by 20 percent of patients in 1991 and but only 15 percent by 19%.
Characteristics of Study Subjects
Persons prescribed medication compared to those with no prescription. Table 1 lists the characteristics of treated schizophrenia patients prescribed antipsychotics (n = 4,080) versus schizophrenia patients with no prescription claims (n = 1,060). The year 1995 was considered a representative time period. Significant differences were found in persons with no prescription claims in that they were more likely to be male (62% vs. 56%; x 2 = 9.66, df= l,p = 0.002), more likely to be African-American (64% vs. 56%; x 2 = 30.25, df=2,p = 0.001), younger (mean = 38.7 years, standard deviation [SD] = 10.9, vs. 41.4 years, SD = 11; t = 7.03, p = 0.00001), and less chronically disabled-that is, fewer received Supplemental Security Income (SSI) benefits (58% vs. 82%; x 2 = 287.03, df = 1, p = 0.001)-than individuals with antipsychotic prescriptions. Additionally, the no-prescription group had a shorter period of enrollment in Medicaid (9.3 months, SD = 3.9, vs. 11.5 months, SD = 1.6; t = 18.57, p = 0.0001) and higher hospitalization rates (32% vs. 29%; x 2 = 3.738, df= \,p = 0.05). Thus, the no-prescription group members tended to be young African-American males with acute, rather than persistent, schizophrenia who were not well connected to the outpatient system and received medical assistance benefits.
Persons prescribed antipsychotics. With respect to subject characteristics, table 2 shows a number of significant differences in sociodemographics and service histories between subjects in the conventional and the atypical categories and within the atypical category itself. All sub- jects were eligible for Medicaid for an entire year following the receipt of their first prescription in 1995 (n = 2,951). Subjects in the conventional category were more likely to be African-American (56% conventional vs. 51% newer atypical and 43% clozapine; x 2 = 33.84, df= 4, p = 0.001) and older (43 years, SD = 11, for conventional; 40.5 years, SD = 10.3, for newer atypical; and 39.5 years, SD = 9.2, for clozapine; F = 20.46, df= 2,2948, p = 0.0001).
With respect to the treatment history prior to the indexed medication, 84 percent of subjects in both the conventional and atypical groups and 93 percent of those in the clozapine category were prescribed an antipsychotic medication in the 6-month period prior to their indexed prescription in the study year. Those on conventional medications had significantly lower psychiatric hospitalization rates when compared with the atypical group; however, the lowest psychiatric hospitalization rates were for those prescribed clozapine (20% for conventional category vs. 31% for atypical vs. 18% for clozapine; x 2 = 28.52, df= 2, p = 0.001). Emergency room (ER) use was similar to hospitalization in that the conventional group had lower ER rates than the atypical group, and clozapine subjects had the lowest ER rates (13% for conventional vs. 15% for atypical vs. 7% for clozapine group; \ 2 = 10.82, df = 2,p = 0.004).
The use of two other services, partial hospitalization and intensive case management, suggested that the atypical group's members were more involved with or connected to the outpatient service system than those in the conventional category; for example, atypical group members had the highest rates of both partial care and intensive case management as well as higher inpatient and ER use than those prescribed conventional agents. Partial care rates were 40 percent for conventional subjects versus 44 percent for the atypical group versus 53 percent for the clozapine group (x 2 = 18.9, df=2,p = 0.001). Intensive case management rates were 30 percent for the conventional group versus 43 percent for the atypical group versus 67 percent for the clozapine group (x 2 = 162.89, df = 2, p = 0.001). Table 3 shows duration, switching, and concurrent use of antidepressants, based on the indexed antipsychotic prescription in 1995. Those prescribed conventional agents had a slightly longer duration on medication compared to those on atypicals, with the clozapine group having the longest duration as well as the fewest interruptions or months of no filled prescriptions (8.1 months' duration, SD = 3.5, for conventional vs. 7.4 months, SD = 4.0, for atypicals vs. 11 months, SD = 2.6, for clozapine subjects [F = 105.78, df = 2,2948, p = 0.0001]). When we looked at duration on any antipsychotic agent during the year, regardless of which one was indexed, we found no difference in overall duration between conventional and atypical groups (conventional Note.-SD = standard deviation; SSI = Supplemental Security Income. 1 Subset of subjects receiving antipsychotic prescription who were corrtinuousiy enrolled in medical assistance program during a year period following their Indexed prescription.
Patterns of Utilization.
group duration was 8.6 months, SD = 3.2, and atypical 8.8 months, SD = 3.3, with clozapine subjects again having the most stable pattern at 11.3 months, SD = 2.1 [F = 94.1, df= 2,2948, p = 0.0001]). Taken together, these findings disprove our hypothesis that individuals prescribed atypicals will remain on their medication for longer periods, according to recommendations.
Consistent with the duration findings, the clozapine group had the least amount of interruptions with respect to months prescribed medications during the year compared to the atypical group, which had the most (47% of those in the atypical antipsychotic group had no interruptions compared to 53% of the conventional group; 84% in the clozapine group had no interruptions during the year [x 2 = 116.01, etf= 2, p = 0.001]). Note.-SD = standard deviation. 1 Subset of subjects receiving antipsychotJc prescription who were continuously enrolled in medical assistance program during a year period following their indexed prescription. 2 Categories are not mutually exclusive as individuals can be in more than one state during the year.
In examining "switching" patterns during the followup year using the indexed prescription in 1995, our data showed that the highest percentage of people switching to another medication were those on atypicals (58%, vs. 38% for clozapine and 25% for conventional antipsychotics; x 2 = 98.84, df=2,p = 0.0001). Interestingly, of those who switched, the conventional group members were more likely to return to the same medication following their interruption (65% for conventional group vs. 38% atypical vs. 35% clozapine; x 2 = 68.23, df=2,p = 0.003). The hypothesis regarding concurrent use of antidepressants was also not bome out by the results. We found that subjects who were prescribed atypical medications had a higher rate of antidepressant prescriptions (44% for atypical group vs. 31% for conventional and 28% for clozapine; x 2 = 29.14, df=2,p = 0.0001).
In examining the treatment utilization patterns of patients receiving antipsychotic prescriptions in the year following their indexed prescription, those on atypicals had the highest rates of hospitalization (36% for atypical group vs. 28% for conventional and 21% for clozapine; x 2 = 21.05, df = 2,p = 0.0001), whereas the clozapine group had the highest rate of intensive case management (70% for clozapine group vs. 48% for atypical vs. 35% for conventional; x 2 = 148.23, df= 2, p = 0.0001).
Discussion
The results of this study of a large northeast urban population indicate that more than 80 percent of public sector schizophrenia patients were prescribed some type of antipsychotic medication to manage their symptoms. This level falls within the range reported by McCombs et al. (1999) , who found a 76 percent prescription rate in Medicaid patients with a diagnosis of schizophrenia, and the PORT study on schizophrenia (Lehman 19986) , which found a 92 percent utilization rate in a random sample of outpatient subjects. Based on current reports of a 50 percent use rate of atypicals (Lehman 1999; Glazer 2000; Wang et al. 2000) , our 39 percent atypical use rate in 1996 appears consistent with the general trend. Surprisingly, data from a survey done by the Bazelon Center for Mental Health Law found access to atypical antipsychotics even better in the Medicaid program than under private insurance (Anonymous 2000) , but access was based not on pharmacy records but on formulary policies. This led to questions about the survey results (Glazer 2000) , because access may not translate into actual use rates because of caps on monthly prescriptions, copayments, and prior authorization requests. Although our study results may not be generalized to Medicaid programs with different formulary restrictions or to the private sector population seen primarily by psychiatrists in office-based practices, results from these analyses are relevant to a sizable group of seriously mentally ill individuals treated in the public sector through the Medicaid program. Given the accumulation of evidence indicating that newer atypicals should be the first order of treatment, why are conventional medications still prescribed? One explanation may be that because the newer atypical medications do not come in an injectable form, depot maintenance is recommended as the only alternative for individuals who have difficulty maintaining a regime of oral medication. The use of depot has, however, decreased from 20 percent to 15 percent between 1991 and 1996 when compared to 35 percent of the PORT study outpatient population on depot in 1993. Another explanation for the use of conventional agents is that providers in public mental health clinics may choose not to switch patients who are stabilized and doing well on older medications because of an increased risk of exacerbation of symptoms. However, it seems that for patients experiencing a relapse while on conventional medications, the newer atypicals would be the preferred choice (Norquist and Hyman 1999). Our findings provide some evidence for this; we see more use of newer atypical agents in patients who have been hospitalized, similar to the results found by Leslie and Rosenheck (2001) for VA patients. Furthermore, our study subjects had higher rates of emergency room and intensive case management services, perhaps giving clinicians an opportunity to try a newer atypical medication while the patient was under some degree of supervision.
What is striking in these data is the fact that AfricanAmericans are both less likely to be prescribed an antipsychotic agent at all (table 1) and less likely to receive a clozapine prescription. Given the similarity in our study subjects with respect to diagnosis, income, insurance coverage, and access to community outpatient services, prescription pattern variation cannot be easily explained by these data (Kuno and Rothbard 2002) . Leslie and Rosenheck (2001) also found African-Americans in the VA system less likely to be prescribed clozapine, after the authors controlled for patient and facility characteristics. A study is currently under way by investigators to examine factors such as geographic location of provider and patient and provider attitudes and interactions to explain this disparity more clearly.
To our surprise, we found no increase in duration of use of atypicals, when compared to conventional medications such as haloperidol. Overall, our results did not support our hypotheses, which posited that we would see longer duration, less switching behavior, and lower concurrent use of antidepressants with atypicals. Duration on newer atypicals is significantly shorter than on conventional agents, although when we summed the months on the indexed prescription with any antipsychotic medication prescribed during the same year, duration was about 8 months for both groups. Only in clozapine patients is duration on medication longer, switching behavior less, and use of complementary antidepressants lower when compared to patients on conventional medications. In particular, the higher use of antidepressants with atypicals other than clozapine is difficult to explain, given that atypicals are purported to have mood-stabilizing properties and are said to be used as a single therapy to treat symptoms of psychosis and depression in patients with schizophrenia (Hillert et al. 1992; Glazer 1997) .
For all study patients, duration on medication fell short of the 1-year treatment period recommended by the PORT study and APA guidelines. Loss of Medicaid eligibility might be a possible explanation for shortened duration in some instances, but in this situation we controlled for time by requiring continuous Medicaid coverage for our study subjects. Unlike other welfare recipients, who may move in and out of eligibility, between 86 percent and 89 percent of the antipsychotic medication group qualified for SSI benefits and had long stays on welfare and Medicaid. Another more plausible explanation for our unexpected findings on duration and switching behavior is the fact that our population consists of patients in communitybased treatment settings who have multiple problems such as drug abuse, criminal/legal issues, and residential instability when compared to subjects in clinical trials. Adherence to medication regimes for patients in real-world settings is arguably one of the most difficult problems to address. Perhaps the longer duration seen in clozapine patients is due in part to the fact that these individuals are more cooperative and compliant with medication because they must follow strict medication monitoring requirements involving blood tests and are generally under the supervision of intensive case managers.
Conclusions
Few would disagree with the contention that the rates and patterns of medication use in naturalistic community settings like ours are extremely important from a policy perspective and essential to cost-effectiveness and cost-benefit evaluations, given that most studies come from drug trials, which use stricter participation criteria. The potential shown in clinical trials for atypicals to reduce both the extrapyramidal side effects typically associated with antipsychotic agents as well as rates of depression provides hope that the atypicals will lead to greater treatment compliance and an overall improvement in symptoms. However, our data show no marked shift in duration of use or switching behavior between the newer atypicals and conventional agents. Like the PORT study (Lehman et al. 1998a (Lehman et al. , 1998 and the study of McCombs et al. (1999) , this study found that antipsychotics are not meeting the therapeutic needs of patients with schizophrenia, indicating that the problem continues to exist in naturalistic settings even with the advent of "newer" atypicals. A better understanding of the dynamics and characteristics of patients and providers in community settings is needed to reduce symptoms, increase treatment compliance, and improve quality of life. Without adherence to medication therapies, treatment effectiveness cannot be achieved. We suggest replication of these findings for similar populations in different geographical sites and for commercial and health maintenance populations, which represent a smaller subset of patients with schizophrenia. Prospective studies of the effectiveness of the newer atypicals with acute populations are also required to answer these questions.
